BridgeBio Pharma (BBIO) shares have been volatile lately, recently dropping 4.75% following AstraZeneca’s announcement that its CARDIO-TTRansform trial failed to meet its primary endpoint, impacting competitive expectations for BridgeBio’s drug, Attruby. Despite this, the company has seen a strong yearly return of 84.83% and has a fair value assessment of $102.71, suggesting it is undervalued at its current price of $85.89. BridgeBio’s future hinges on successful late-stage trial results and the ability to navigate market challenges. While its DCF model suggests considerable upside potential, the stock is priced at a premium compared to industry averages, raising questions about future growth sustainability.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/bridgebio-pharma-bbio-following-wainua-trial-setback-still-l
